Using loratadine to prevent bone pain from G-CSF during stem cell transplants

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates whether loratadine is more effective than a placebo in preventing bone pain associated with G-CSF during autologous hematopoietic stem cell transplants in patients with lymphoma or multiple myeloma. The trial will involve adult participants who meet specific eligibility criteria, including a documented diagnosis of lymphoma or multiple myeloma and the need for a stem cell transplant. Participants will be randomly assigned to receive either loratadine or a placebo, and the severity of bone pain will be monitored throughout the treatment period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. A histologically or cytologically documented lymphoma or multiple myeloma
2. Next line of therapy is autologous stem cell transplant
3. Adult ≥ 18 years old.
4. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2.
5. Life expectancy of at least 12 weeks.
6. The absence of any additional poorly controlled systemic disease that is directly contraindicated or places subject at significant risk, including but not limited to: congestive heart failure, diabetes mellitus, cirrhosis or liver failure, renal failure.
7. Able to adhere to study protocols and visit schedules

Exclusion Criteria:

1. Hypersensitivity or intolerance to antihistamines
2. Use of antihistamines within two days prior to the study period, excepting the use of single dose antihistamines during chemotherapy or blood transfusion protocols.
3. Recent use of G-CSF or pegfilgrastim defined as within 12 weeks of study accrual.
4. New and continued regular use of analgesics within the four days prior to the first dose of G-CSF

Where it's running

• Cross Cancer Institute
  Edmonton, Alberta, Canada Recruiting

Study contacts

• Study coordinator: Michael Chu, MD
• Email: Michael.Chu@ahs.ca
• Phone: 780-432-8757

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining ruxolitinib with corticosteroids for severe acute graft‑versus‑host disease

  This trial tests whether adding ruxolitinib to corticosteroids as first‑line treatment helps people who develop severe acute graft‑versus‑host disease after a first stem cell transplant.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing · NCT07509749

• Venetoclax added to reduced-intensity conditioning for combined stem cell and kidney transplant

  This trial tests whether adding venetoclax to a reduced-intensity conditioning regimen is safe for adults with blood cancers who are receiving a combined stem cell and kidney transplant from a matched or partially matched donor.

  Recruiting Early Phase 1 Massachusetts General Hospital · Boston, Massachusetts · NCT07358195

• First-line ruxolitinib plus corticosteroids for grade II acute graft-versus-host disease

  This trial will test whether adding ruxolitinib to standard corticosteroids helps people with new grade II acute graft-versus-host disease after an allogeneic stem cell transplant.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07340723

• Individualized ATG dosing for stem cell transplantation

  This study is testing a personalized approach to dosing a medication for adults receiving stem cell transplants to see if it can reduce complications like infections and improve recovery.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing · NCT06572462

• Digital application to improve sexual health for stem cell transplant survivors

  This study is testing a new app to help survivors of stem cell transplants improve their sexual health and overall well-being.

  Recruiting Massachusetts General Hospital · Coral Gables, Florida and 2 other locations · NCT06541002

• Modified second transplantation for patients with graft failure

  This study is testing a new approach to a second stem cell transplant for patients who didn't fully recover after their first transplant to see if it helps them get better, especially with their platelet counts.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT06512545

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.